1350925-20-0 Usage
Description
6-Chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one is a heterocyclic chemical compound with a molecular formula C8H6ClN3O. It features a pyridine ring fused with a dihydropyrazinone ring, and the presence of a chlorine atom at the 6-position imparts unique properties to the molecule. 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one is recognized for its potential biological activities, such as anti-cancer and anti-inflammatory effects, and is being explored as a drug candidate for the treatment of various diseases. The synthesis and characterization of 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one are active areas of research in medicinal chemistry and pharmaceuticals.
Uses
Used in Pharmaceutical Industry:
6-Chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one is used as a drug candidate for its potential anti-cancer properties, targeting the treatment of various types of cancer. Its anti-inflammatory effects also make it a candidate for the development of medications aimed at reducing inflammation and associated symptoms in different conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one serves as a subject of ongoing research for its synthesis and characterization. This research is crucial for understanding the compound's structure-activity relationship, which can guide the development of more effective and safer drugs based on its molecular structure.
Check Digit Verification of cas no
The CAS Registry Mumber 1350925-20-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,9,2 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1350925-20:
(9*1)+(8*3)+(7*5)+(6*0)+(5*9)+(4*2)+(3*5)+(2*2)+(1*0)=140
140 % 10 = 0
So 1350925-20-0 is a valid CAS Registry Number.
1350925-20-0Relevant articles and documents
OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION
-
, (2019/10/23)
The present disclosure relates to compounds of Formula (I), its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
-
Page/Page column 341; 342, (2016/04/26)
The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
Paragraph 00641, (2014/10/04)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
